Speakers

Alan Liu, VP (Wanbang BioPharma) Fosun Pharmaceuticals, China (tbc)

Andrew McMillan, Principal, 5AM Ventures, USA

Barbara Yanni / Pamela Domain, Merck, USA (tbc)

Cecile Tharaud, CEO, INSERM-Transfert, Paris, France

Cedric Bisson Managing Partner, Life Science, iNovia Capital, Canada

Cheryl Reicin, Partner, Torys, Toronto and New York, Canada / USA

Chris Yochim, AstraZeneca (tbc)

Dan Omstead,President & CEO, H&Q Capital Management, USA

David Allen, Chairman, YM Biosciences, Canada

David Brener, Director, Research & Development Alliances, Medical Division, Pfizer, Canada

David McNaughton, Head Monetization Fund, DRI Capital, Canada

Donna See, Director Strategic Initiatives, Columbia University, USA

Erich L. Grimm, Executive Director, Drug Discovery Services, Pharmaron,  USA

Frank Stonebanks, Ontario Institute of Cancer Research, Canada

Fred Rheinart, RheinhartConsulting & exVP AUTM, USA

Garold Breit, Executive Director, Technology Transfer Office, University of Manitoba, Canada

Graeme McRae, Chairman, President & CEO, Bioniche, Canada

Hon. Glen Murray, Ontario Ministry of Research and Innovation, Canada

Jasbir (Jesse) Kindra, Washington State University, USA

Jeff Ullmer, Global Head, External Research, Novartis, Boston, USA

Jessica Chutter, MD, Morgan Stanley, Canada

Jim McCloughlin, Pfizer, USA (tbc)

John Milloy, Ontario Minister of Research and Innovation, Canada

Jon Northrup, COO, Jubilant Innovation, India - USA

Kathryn Hayashi, CFO, Centre for Drug Research and Development, Canada

Kevin Noonan, Partner, MBHB, Chicago, USA

Maarten de Jong, MD, Barclays Capital, USA

Marcus Kostka, Collaborative Research, Boehringer Ingelheim, Germany

Mark Lievonen, President, sanofipasteur, Canada

Mark Rohrbaugh, Director, Technology Transfer, NIH, USA

Michael Hayden, Xenon (Prix Galien), Canada

Michael Midmer, Director, Rosetta Capital, Canada

Natalie Dakers, CEO, Centre for Drug Research and Development, Canada

Pamela Domain, Merck, USA (tbc)

Parimal Nathwani, VP, Commercialization, Life Sciences, MaRS Innovation, Canada

Paul Ranson, Partner, Head of Life Science, Fasken Martineau, UK

Peter Brenders, CEO, BioteCanada, Canada

Peter Luke, Pfizer, UK (tbc)

Peter Van Der Velden, CEO, Lumira Capital, Canada

Petra Sansom, Global Alliances Director, Roche, USA (tbc)

Phil Ross, MD, JPMorgan, USA (tbc)

Richard Mitchell, Director of Business Development, Fred Hutchinson Cancer Center, Seattle, USA

Savino Dipasquale, VP Business Development, GSK, Canada

Shiv Krishnan, Director, Scouting & Partnering, Sanofi Aventis, USA

Steve Meller, Global Innovation Catalyst, Procter & Gamble, USA

Steven Xanthoudakis, Merck & Co, Canada

Tony Cruz, CEO, Transition Therapeutics, Canada

Tony Sedgwick, CEO, Novacta, UK

Vanessa Grant, Partner, McCarthy Tetrault, Canada

Wes Blakeslee, Executive Director, Tech Transfer Office, John Hopkins, USA

Organized by:

•